KR20230026493A - Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 - Google Patents
Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 Download PDFInfo
- Publication number
- KR20230026493A KR20230026493A KR1020237002565A KR20237002565A KR20230026493A KR 20230026493 A KR20230026493 A KR 20230026493A KR 1020237002565 A KR1020237002565 A KR 1020237002565A KR 20237002565 A KR20237002565 A KR 20237002565A KR 20230026493 A KR20230026493 A KR 20230026493A
- Authority
- KR
- South Korea
- Prior art keywords
- rcc
- cancer
- lenvatinib
- hif
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042307P | 2020-06-22 | 2020-06-22 | |
| US63/042,307 | 2020-06-22 | ||
| US202163146915P | 2021-02-08 | 2021-02-08 | |
| US63/146,915 | 2021-02-08 | ||
| PCT/US2021/038172 WO2021262563A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230026493A true KR20230026493A (ko) | 2023-02-24 |
Family
ID=79281740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237002565A Pending KR20230026493A (ko) | 2020-06-22 | 2021-06-21 | Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210838A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4168008B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7750884B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230026493A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115803629A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021296151A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026094A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183852A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3072250T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022016406A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262563A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4425678A1 (en) | 2023-02-28 | 2024-09-04 | LG Energy Solution, Ltd. | Separator for electrochemical device and electrochemical device comprising same |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| US20240327929A1 (en) * | 2021-08-12 | 2024-10-03 | Merck Sharp & Dohme Llc | Dosage regimen for administration of belzutifan |
| JPWO2024204679A1 (cg-RX-API-DMAC7.html) * | 2023-03-31 | 2024-10-03 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| EP3866927A4 (en) * | 2018-10-17 | 2022-07-27 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2021
- 2021-06-21 JP JP2022578935A patent/JP7750884B2/ja active Active
- 2021-06-21 CN CN202180049537.5A patent/CN115803629A/zh active Pending
- 2021-06-21 KR KR1020237002565A patent/KR20230026493A/ko active Pending
- 2021-06-21 MX MX2022016406A patent/MX2022016406A/es unknown
- 2021-06-21 ES ES21828761T patent/ES3072250T3/es active Active
- 2021-06-21 US US18/009,115 patent/US20230210838A1/en active Pending
- 2021-06-21 EP EP21828761.3A patent/EP4168008B1/en active Active
- 2021-06-21 BR BR112022026094A patent/BR112022026094A2/pt unknown
- 2021-06-21 EP EP26162704.6A patent/EP4775271A2/en active Pending
- 2021-06-21 CA CA3183852A patent/CA3183852A1/en active Pending
- 2021-06-21 WO PCT/US2021/038172 patent/WO2021262563A1/en not_active Ceased
- 2021-06-21 AU AU2021296151A patent/AU2021296151A1/en active Pending
-
2022
- 2022-12-16 MX MX2025014865A patent/MX2025014865A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4425678A1 (en) | 2023-02-28 | 2024-09-04 | LG Energy Solution, Ltd. | Separator for electrochemical device and electrochemical device comprising same |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022016406A (es) | 2023-01-30 |
| MX2025014865A (es) | 2026-01-07 |
| EP4168008A4 (en) | 2024-08-07 |
| EP4775271A2 (en) | 2026-07-15 |
| BR112022026094A2 (pt) | 2023-01-17 |
| CN115803629A (zh) | 2023-03-14 |
| ES3072250T3 (en) | 2026-06-30 |
| JP2023531675A (ja) | 2023-07-25 |
| JP7750884B2 (ja) | 2025-10-07 |
| AU2021296151A1 (en) | 2023-02-02 |
| EP4168008A1 (en) | 2023-04-26 |
| EP4168008B1 (en) | 2026-03-18 |
| CA3183852A1 (en) | 2021-12-30 |
| WO2021262563A1 (en) | 2021-12-30 |
| US20230210838A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2904880T3 (es) | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| US11395821B2 (en) | Treatment of EGFR-driven cancer with fewer side effects | |
| JP6464085B2 (ja) | 神経膠芽腫の治療のための併用療法 | |
| JP2020040992A (ja) | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| JP2026079825A (ja) | 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害 | |
| JP7579636B2 (ja) | 膵がん治療のための組み合わせ治療薬 | |
| Scaringi et al. | Combining molecular targeted agents with radiation therapy for malignant gliomas | |
| JP2024527109A (ja) | Kras変異体がんの処置のための方法および組成物 | |
| Paudel et al. | Targeting lung cancer using advanced drug delivery systems | |
| WO2023100131A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer | |
| JP2023531930A (ja) | PD-1アンタゴニスト、HIF-2α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| JP6754785B2 (ja) | 免疫治療投与レジメンおよびその組合せ | |
| RU2858600C2 (ru) | Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| Steendam et al. | Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma | |
| CN109963847A (zh) | 治疗实体瘤的方法 | |
| HK40087480A (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib | |
| JP2016502974A (ja) | Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 | |
| US20210113692A1 (en) | Dosing regimen | |
| JP2020510058A (ja) | トリフルリジン/チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 | |
| US20210346520A1 (en) | Methods of using intravenous rexin-g: a tumor-targeted retrovector encoding a dominant-negative cyclin g1 (ccng1) inhibitor for advanced pancreatic cancer | |
| EP4637821A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |